CLAIMS

1. Use of a compound selected from the group consisting of elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), and a pharmaceutically acceptable salt of elafibranor or GFT1007, in the manufacture of a pharmaceutical composition for treating primary biliary cholangitis (PBC) in a subject having PBC with a baseline plasma alkaline phosphatase (ALP) level of more than 1.67xULN and at most 3xULN.

2. Use of a compound selected from the group consisting of elafibranor, GFT1007, and a pharmaceutically acceptable salt of elafibranor or GFT1007, in the manufacture of a pharmaceutical composition for reducing baseline plasma ALP level in a subject having PBC with a baseline plasma ALP level of more than 1.67xULN and at most 3xULN.

3. The use according to claim 1 or 2, wherein the composition comprises elafibranor or a pharmaceutically acceptable salt thereof.

4. The use according to any one of claims 1 to 3, wherein the composition comprises elafibranor.

5. The use according to any one of claims 1 to 4, wherein said composition is formulated in a form selected from the group consisting of a gel, an oil, a pill, a tablet, a powder, a gel cap, a capsule, and a galenic form or device assuring a prolonged and/or slow release.

6. The use according to any one of claims 1 to 5, wherein said composition is formulated in a form of a tablet.

7. The use according to any one of claims 1 to 6, wherein elafibranor is to be administered once a day.

8. The use according to any one of claims 1 to 7, wherein the pharmaceutical composition is to be administered orally.

9. The use according to any one of claims 1 to 8, wherein elafibranor, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid (GFT1007), a pharmaceutically acceptable salt of elafibranor or GFT1007 is to be administered at a dose of 80 mg or 120 mg per administration.

10. The use according to any one of claims 1 to 9, wherein elafibranor is to be administered at a dose of 80 mg per administration.

11. The use according to any one of claims 1 to 10, wherein the subject having PBC with a baseline alkaline phosphatase (ALP) level of more than 1.67xULN and at most 3xULN, has an inadequate response to ursodeoxycholic acid (UDCA).

12. The use according to any one of claims 1 to 11, wherein the pharmaceutical composition is to be administered in combination with another anti-cholestatic agent, preferably the other anti-cholestatic agent being ursodeoxycholic acid (UDCA) to the subject.

13. The use according to any one of claims 1 to 12, wherein elafibranor is to be administered at a dose of 80 mg per administration in combination with ursodeoxycholic acid (UDCA), to the subject .

14. The use according to any one of claims 1 to 13, wherein elafibranor is to be administered at a dose of 80 mg per administration in combination with ursodeoxycholic acid (UDCA), to a subject having primary biliary cholangitis (PBC) with a baseline alkaline phosphatase (ALP) level more than 1.67xULN and at most 3xULN and an inadequate response to ursodeoxycholic acid.